Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals (SYRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 196,926
  • Shares Outstanding, K 42,441
  • Annual Sales, $ 2,050 K
  • Annual Income, $ -62,280 K
  • 60-Month Beta 1.46
  • Price/Sales 98.13
  • Price/Cash Flow N/A
  • Price/Book 2.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.47
  • Number of Estimates 5
  • High Estimate -0.38
  • Low Estimate -0.59
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +12.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.53 +0.56%
on 11/21/19
5.40 -15.64%
on 11/07/19
-0.55 (-10.85%)
since 11/06/19
3-Month
4.53 +0.56%
on 11/21/19
11.93 -61.81%
on 09/13/19
-5.05 (-52.60%)
since 09/06/19
52-Week
4.53 +0.56%
on 11/21/19
11.93 -61.81%
on 09/13/19
-2.94 (-39.26%)
since 12/06/18

Most Recent Stories

More News
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that...

AXLA : 3.53 (-21.38%)
DNLI : 18.32 (+0.77%)
EVLO : 4.26 (-5.12%)
KLDO : 5.91 (-7.94%)
MRNA : 19.99 (-3.15%)
RUBY : 9.72 (-6.00%)
MCRB : 3.53 (-4.08%)
SYRS : 4.56 (-1.72%)
Syros to Present at Piper Jaffray 31st Annual Healthcare Conference

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate...

SYRS : 4.56 (-1.72%)
Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the company and its collaborators from the Whitehead Institute for...

SYRS : 4.56 (-1.72%)
Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Tops Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 2.08% and 29.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

SYRS : 4.56 (-1.72%)
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 92.28 (+0.70%)
AXLA : 3.53 (-21.38%)
DNLI : 18.32 (+0.77%)
EVLO : 4.26 (-5.12%)
KLDO : 5.91 (-7.94%)
MRNA : 19.99 (-3.15%)
RUBY : 9.72 (-6.00%)
MCRB : 3.53 (-4.08%)
SYRS : 4.56 (-1.72%)
Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

--Presented New Preclinical Data on SY-5609 at AACR-NCI-EORTC Conference

SYRS : 4.56 (-1.72%)
Syros to Present on Sickle Cell Disease Research at 61st Annual ASH Meeting

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present on its identification and validation of a novel...

SYRS : 4.56 (-1.72%)
Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET...

SYRS : 4.56 (-1.72%)
Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference

--Deeper and More Sustained Responses Associated with RB Pathway Alterations

SYRS : 4.56 (-1.72%)
Syros Pharmaceuticals Enters Oversold Territory

Syros Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

SYRS : 4.56 (-1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade SYRS with:

Business Summary

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients...

See More

Key Turning Points

2nd Resistance Point 4.87
1st Resistance Point 4.75
Last Price 4.56
1st Support Level 4.57
2nd Support Level 4.51

See More

52-Week High 11.93
Fibonacci 61.8% 9.10
Fibonacci 50% 8.23
Fibonacci 38.2% 7.36
Last Price 4.56
52-Week Low 4.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar